Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lucid Diagnostics (LUCD) Shares Outstanding (2021 - 2025)

Lucid Diagnostics' Shares Outstanding history spans 5 years, with the latest figure at $131.1 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 107.86% year-over-year to $131.1 million; the TTM value through Dec 2025 reached $131.1 million, up 107.86%, while the annual FY2025 figure was $131.1 million, 107.86% up from the prior year.
  • Shares Outstanding reached $131.1 million in Q4 2025 per LUCD's latest filing, roughly flat from $130.9 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $131.1 million in Q4 2025 to a low of $13625.0 in Q1 2023.
  • Average Shares Outstanding over 5 years is $39.2 million, with a median of $36.5 million recorded in 2022.
  • Peak YoY movement for Shares Outstanding: tumbled 99.96% in 2023, then soared 338541.34% in 2024.
  • A 5-year view of Shares Outstanding shows it stood at $34.9 million in 2021, then grew by 16.04% to $40.5 million in 2022, then crashed by 99.95% to $18625.0 in 2023, then skyrocketed by 338541.34% to $63.1 million in 2024, then soared by 107.86% to $131.1 million in 2025.
  • Per Business Quant, the three most recent readings for LUCD's Shares Outstanding are $131.1 million (Q4 2025), $130.9 million (Q3 2025), and $101.8 million (Q2 2025).